Discover

(Redirected from The Institute for OneWorld Health)
The 'Institute for OneWorld Health' is a nonprofit pharmaceutical company founded in 2000 to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing countries.

Contents

Drug development efforts

Executives

Major supporters

References

External links

Drug development efforts

Currently, two drugs are under development a drug to treat Chagas disease in Latin America and a drug to cure visceral leishmaniasis in India. Paromomycin, the drug being developed to treat visceral leishmaniasis, was granted orphan drug status in 2005 by both the FDA and EMEA.^[1] Prior to this approval, Phase 3 clinical trials for this were conducted in India in 2003—2004. The overall conclusion was that and were similar to the comparison agent in the trials, amphotericin B, results which in August 2006 led to approval for treatment of visceral leishmaniasis by the Indian government.^[2]

Executives

★ Dr. Victoria Hale Ph.D., CEO and Chairman of the Board of Directors.

★ Dr. Ahvie Herskowitz M.D., COO and Chief Medical Officer.

Major supporters

★ Bill & Melinda Gates Foundation^[3][4] (the Institute received 96% of its funding from the Foundation as of 2006)^[5]

★ Amgen, Chiron Corporation, Gap, Lehman Brothers, Pfizer, Vital Spark Foundation, Skoll Foundation

References

1.
US FDA and EMEA grant “Orphan Drug” designation for paromomycin injection to treat visceral leishmaniasis (abstract preserved by National Health Service)
2.
Injectable Paromomycin for Visceral Leishmaniasis in India, , Shyam, Sundar, New England Journal of Medicine,
3.
4.
5. Curing the Third World Angela Rickabaugh Shears

External links

★ The Institute for OneWorld Heath Official Website